Deutsche Bank AG reduced its stake in shares of Eloxx Pharmaceuticals (OTCMKTS:ELOX) by 42.5% during the 4th quarter, according to its most recent filing with the SEC. The firm owned 25,963 shares of the company’s stock after selling 19,194 shares during the period. Deutsche Bank AG’s holdings in Eloxx Pharmaceuticals were worth $311,000 at the end of the most recent quarter.
A number of other institutional investors and hedge funds also recently made changes to their positions in ELOX. BlackRock Inc. grew its position in Eloxx Pharmaceuticals by 36.9% during the 4th quarter. BlackRock Inc. now owns 1,493,471 shares of the company’s stock worth $17,938,000 after purchasing an additional 402,501 shares during the period. Vanguard Group Inc boosted its stake in shares of Eloxx Pharmaceuticals by 60.0% during the 3rd quarter. Vanguard Group Inc now owns 857,202 shares of the company’s stock worth $14,606,000 after acquiring an additional 321,328 shares in the last quarter. Vanguard Group Inc. boosted its stake in shares of Eloxx Pharmaceuticals by 60.0% during the 3rd quarter. Vanguard Group Inc. now owns 857,202 shares of the company’s stock worth $14,606,000 after acquiring an additional 321,328 shares in the last quarter. Geode Capital Management LLC boosted its stake in shares of Eloxx Pharmaceuticals by 10.0% during the 4th quarter. Geode Capital Management LLC now owns 237,986 shares of the company’s stock worth $2,858,000 after acquiring an additional 21,634 shares in the last quarter. Finally, Bank of America Corp DE boosted its stake in shares of Eloxx Pharmaceuticals by 226.0% during the 4th quarter. Bank of America Corp DE now owns 14,209 shares of the company’s stock worth $171,000 after acquiring an additional 9,851 shares in the last quarter.
Several equities research analysts have recently issued reports on the stock. Canaccord Genuity reissued a “buy” rating and set a $17.00 target price (down from $20.00) on shares of Eloxx Pharmaceuticals in a research note on Wednesday, May 15th. They noted that the move was a valuation call. Zacks Investment Research raised shares of Eloxx Pharmaceuticals from a “hold” rating to a “buy” rating and set a $13.00 target price on the stock in a research note on Monday, May 13th. One analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. The stock has a consensus rating of “Buy” and an average price target of $19.40.
Eloxx Pharmaceuticals (OTCMKTS:ELOX) last posted its earnings results on Thursday, May 9th. The company reported ($0.33) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.41) by $0.08.
WARNING: “Deutsche Bank AG Has $311,000 Holdings in Eloxx Pharmaceuticals (ELOX)” was first published by Ticker Report and is the property of of Ticker Report. If you are viewing this news story on another site, it was stolen and reposted in violation of international trademark & copyright law. The original version of this news story can be read at https://www.tickerreport.com/banking-finance/4353859/deutsche-bank-ag-has-311000-holdings-in-eloxx-pharmaceuticals-elox.html.
About Eloxx Pharmaceuticals
Eloxx Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing novel therapeutics for the treatment of rare and ultra-rare premature stop codon diseases. Its lead program is ELX-02, which is in Phase I clinical trial, which focuses on the treatment of cystic fibrosis and cystinosis patients with diagnosed nonsense mutations.
Recommended Story: What is a trade deficit?
Want to see what other hedge funds are holding ELOX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eloxx Pharmaceuticals (OTCMKTS:ELOX).
Receive News & Ratings for Eloxx Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eloxx Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.